- US-listed companies
- Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc.SONN
Market cap
$3.19M
P/E ratio
Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Sep 30, 2020 | Sep 30, 2021 | Sep 30, 2022 | |
Collaboration revenue | 8 | 30 | 42 | 42 | 41 | 41 | 30 | - | 483,626 | 349,943 |
Research and development | - | - | - | - | - | - | - | 10 | - | 21 |
General and administrative | 4 | 6 | 7 | 6 | 5 | 5 | 6 | 8 | 9 | 9 |
Total operating expenses | 13 | 35 | 54 | 44 | 47 | 46 | 46 | - | 26 | 30 |
Loss from operations | -4,606,355 | -5,544,308 | -11,487,916 | -2,619,888 | -5,235,377 | -5,355,101 | -16,078,222 | -24,237,772 | -25,087,436 | -29,669,359 |
Interest income | - | - | - | - | - | - | - | - | 15 | - |
Foreign exchange loss | - | - | - | - | - | - | - | -48,020 | -22,041 | -52,482 |
Other income | - | - | - | - | - | - | - | - | 125,501 | - |
Net loss | -5,214,119 | -5,725,873 | -12,136,526 | -9,076,572 | -6,794,771 | -6,854,420 | -17,726,384 | -24,265,115 | -24,983,961 | -29,721,841 |
Net loss per share, basic and diluted | - | -0.87 | -0.86 | - | - | - | - | - | - | -6.84 |